{
    "symbol": "RDNT",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-09 14:43:06",
    "content": " There were a number of unusual or onetime items impacting the third quarter including the following: $11.2 million of noncash gain from interest rate swaps, net of amortization of the accumulation of the changes in fair value out of other comprehensive income; $8.1 million change in estimate related to refund liability; $195,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $959,000 expense related to leases of our de novo facilities under construction that have yet to open their operations; and $7.8 million of pre-tax losses related to our AI reporting segment. Also affecting net income in the third quarter of 2022 were certain noncash expenses and unusual items including the following: $3.3 million of noncash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $247,000 gain on the disposal of certain capital equipment; $959,000 of non-operational rent expense associated with unopened de novo locations; and $648,000 of non-cash amortization of deferred financing costs and loan discounts related to financing fees paid as part of our existing credit facilities."
}